TEST REPORT

2026CS0716

DATE OF RECEPTION
Date Format: dd/MM/yyyy 16/03/2026

DATE TESTS
Starting: 16/03/2026
Ending: 16/04/2026

APPLICANT

KONE LABS SA DE CV
RIO POTOMAC 153 CASTRO DEL RÍO PARQUE TECNOINDUSTRIAL
MX-36814 Irapuato
Mexico

Att. Amy Rodríguez Rodríguez

IDENTIFICATION AND DESCRIPTION OF SAMPLES

Reference by AITEX	Reference by customer	AITEX sample description
2026CS0716-S01	ÁUREA·L	Stick

TESTS CARRIED OUT

- DETERMINATION OF THE FACTOR OF SUN PROTECTION (SPF) IN VIVO.

Asociación de Investigación de la Industria Textil y Cosmética – C.I.F.: G03182870

DESCRIPTION OF SAMPLES

Reference by AITEX*:* 2026CS0716-S01

Reference by customer*:*

ÁUREA·L

AITEX sample description*:*

Stick

RESULTS

DETERMINATION OF THE FACTOR OF SUN PROTECTION (SPF) IN VIVO

1. OBJECTIVE AND PRINCIPLE OF THE STUDY.

Main objective

The level of sun protection of products with sunscreen is estimated using the erythematous response of the skin to ultraviolet (UV) radiation .

The sun protection factor (SPF) is the ratio of the energy needed to elicit a minimal erythematous response with and without sunscreen applied to the skin of a volunteer

2. TYPE OF STUDY.

ISO 24444:2019/A1:2022

The method uses a solar simulator with a lamp in xenon arc (or equivalent) with a defined and known output. The UV light is emitted on a section of the skin of each volunteer without any protection, while another section is exposed after the application of the product with the sunscreen that is being tested. For the validation of the test, a section of the additional skin is exposed to UV light after the application of a sunscreen product whose SPF is of reference

The response of the skin is visually evaluated according to the presence of redness in a period between 16-24 h after exposure to UV radiation, according to the opinion of the dermatologist investigator

The minimum erythematous dose for unprotected skin (MEDu) and the minimum erythematous dose for protected skin (MEDp), that is, after the application of a product with sunscreen, are the parameters obtained after the test

The minimum erythematous dose (MED) is expressed in terms of energy (mJ x cm-2), or MED units or in units of time (seconds)

The individual sun protection factor (SPFi) for each subject tested is determined as an individual ratio of MEDp / MEDu. The SPF of the product is the arithmetic mean of all the SPFi obtained.

3. TECHNICAL TEAM.

Asociación de investigación de la industria textil y cosmética - AITEX
Technician: ABLD

4. DATE TEST

Starting 25/03/2026
Ending 16/04/2026

5. TESTED PRODUCT REFERENCE

Reference: 2026CS0716-S01

6. RESULTS

The experimental conditions have been the following:

METHODOLOGICAL CRITERIA

- Given the idiosyncrasy of the product under study, the participants met a series of methodological criteria throughout their development, to avoid biases in the data.
- All the participants followed the recommendations that were provided to them at the beginning of the study by the Principal Investigator
- No other product was used that could interfere in the study, in the areas to be tested during the realization of the same

VOLUNTEERS

The number of volunteers whose data have been treated at the end of the trial has been 10. Each of them read, understood and signed an Authorization and Commitment Form

Amount of product applied: 2.00 ± 0.05 mg/cm^2

Gradual progression of the UV dose:

Unprotected sites: an estimated MEDu is used and 6 zones are exposed at increasing UV doses, with a geometrical increase of 1.15

Protected sites: the product to be evaluated is applied and the UV dose is defined based on the expected MEDp. 6 zones are exposed at increasing doses of UV, with a geometrical increase of 1.15

INCLUSION CRITERIA

- Number of volunteers: 10
- Age: 18-65 years
- Gender: Both
- Phototype: I-II-III
- Agree to voluntarily participate in the study and give written informed conse

CRITERIA OF NOT INCLUSION

The criteria for non-inclusion were the following:

The presence of at least one of the following criteria was excluded from the clinical trial:

1. Subjects with acute illness during the study and in the week before the start of this study
2. Presenting cutaneous pathologies in the week before the start of the study
3. Pregnant or lactating women
4. Subjects with allergies to any of the components of the product in

All the volunteers included in this study are aware and exempt from the previous actions, so they are accepted in said study

INFORMATION OF THE SAMPLE

Qualitative composition (INCI) and expected SPF
The customer is responsible for compliance with the data provided

Theoretical protection factor: **50+**

INCI: Dibutyl Adipate, Caprylic/Capric Triglyceride, Diethylamino Hydroxybenzoyl Hexyl Benzoate, Silica, Ozokerite, Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, Oryza Sativa Cera, Methylene Bis-Benzotriazolyl Tetramethylbutylphenol, Hydrogenated Farnesene, Prunus Amygdalus Dulcis Oil, Ethylhexyl Triazone, Calendula Officinalis Flower Extract, Simmondsia Chinensis Seed Oil, Tocopheryl Acetate, Sodium Hyaluronate.

RESULTS AFTER EVALUATION

Skin reactions observed by the researcher:

TABLE 1: Data of the reference product used in this test.

Standard	Average SPF	Acceptance limit (Average ± 2SD)		Conformity
		Lower limit	Upper limit	
P8	52,8	43,9	82,3	Compliance
P2	14,8	13,7	18,5	Compliance

TABLE 2: Data of the tested producto

VOLUNTEERS				SIM	SPF RESULTS							
Nº	Age	Gender	ITA º	watts/ m^2	MED_u		MED_s	MED_p		Standad	SPFs	SPFp
					mm:ss	J/m^2 eff		mm:ss	J/m^2 eff			
1	26	F	53	1582	00:25	204,5	3149,7	26:00	12680,6	P2	15,4	**62**
2	26	M	44	1582	00:35	256,5	3667,4	38:00	16670,2	P2	14,3	**65**
3	18	F	49	1582	00:28	226,6	3444,2	30:00	14728,3	P2	15,2	**65**
4	21	M	45	1582	00:34	250,3	3554,0	37:00	16018,2	P2	14,2	**64**
5	22	F	63	1582	00:21	156,5	2300,6	23:00	10172,8	P2	14,7	**65**
6	44	F	60	1582	00:21	169,8	8526,0	22:00	10954,7	P8	50,2	**64,5**
7	26	M	49	1582	00:28	226,6	11601,4	30:00	14750,9	P8	51,2	**65,1**
8	29	M	37	1582	00:37	302,6	16127,1	39:00	19334,4	P8	53,3	**63,9**
9	33	F	51	1582	00:26	215,4	10853,8	28:00	13804,1	P8	50,4	**64,1**
10	18	f	48	1582	00:32	232,4	13662,8	34:00	14708,4	P8	58,8	**63,3**

Remarks:
SPFs= MEDs/MEDu
SPFi= MEDp/MEDu
MEDu= Minimum erythematous dose (MED) for unprotected skin.
MEDs= Minimum erythematous dose (MED) for standard-protected skin.
MEDp= Minimum erythematous dose (MED) for skin protected with investigational product
SPFs= standard sun protection factor
SPFp= Sun protection factor of the product to be investigated
F = Female
M = Male

CONCLUSION

Results	
Static SPF average	**64,2**
Standard desviation	1,0
Coef "c"	0,7
95% CI	1,2
Conclusion	CI ≤ 17%

Of the 10 volunteers who start the study, they have completed 10

Based on the tables in the previous section, we can conclude that the product referenced as "2026CS0716-S01" evaluated with the UNE EN ISO 24444:2019/A1:2022 standard has obtained the following mean SPF value in vivo carried out in 10 volunteers

SPF 64,2

According to 2006/647/CE, the following labeling is recommended depending on the range of protection factors:

TABLE. Labeling of the sun protection product.

CATEGORY	SPF LABELED	SPF MEASURED
LOW PROTECTION	"6"	6-9.9
	"10"	10-14.9
MEDIUM PROTECTION	"15"	15-19.9
	"20"	20-24.9
	"25"	25-29.9
HIGH PROTECTION	"30"	30-49.9
	"50"	50-59.9
VERY HIGH PROTECTION	"50+"	≥ 60

>>>

Reference by AITEX	Description	Reference by customer
2026CS0716-S01	Stick	ÁUREA·L

Nuria Jorda
Department of Cosmetic Science

Date: 16/04/2026 17:31:04
Digitally Signed by:NURIA JORDA GISBERT -
NIF:21680738H

LIABILITY CLAUSES

1.- AITEX is liable only for the results of the methods of analysis used, as expressed in the report and referring exclusively to the materials or samples indicated in the same which are in its possession, the professional and legal liability of the Centre being limited to these. Unless otherwise stated, the samples were freely chosen and sent by the applicant.
2.- AITEX shall not be liable in any case of misuse of the test materials nor for undue interpretation or use of this document. AITEX laboratories do not carry out sampling.
3.- The Offer and / or Order to which the applicant gives approval through signature and seal, constitutes the Legally Executable Agreement in which AITEX is responsible for safeguarding and guaranteeing the absolute confidentiality of the management of all the information obtained or created during the performance of the contracted activities.
4.- In the eventuality of discrepancies between reports, a check to settle the same will be carried out in the head offices of AITEX. Also, the applicants undertake to notify AITEX of any complaint received by them as a result of the report, exempting this Centre from all liability if such is not done, the periods of conservation of the samples being taken into account.
5.- AITEX will provide at the request of the person concerned, the treatment of complaints procedure. In the event that you want to make it, direct it to: calidad@aitex.es.
6.- AITEX is not responsible for the information provided by customers, which is reflected in the Report, and may affect the validity of the results.
7.- AITEX is not responsible for an inadequate state of the sample received that could compromise the validity of the results, expressing such circumstance, in the test reports.
8.- AITEX may include in its reports, analyses, results, etc., any other evaluation which it considers necessary, even when it has not been specifically requested.
9.- When a Declaration of Conformity is requested, if not indicated otherwise, the decision rule according to ILAC-G8: 2009 will be applied with a security zone of 1U and a Probability of False Acceptance <2.5%.
10.- The uncertainties of tests, which are made explicit in the Results Report, have been estimated for a k = 2 (95% probability of coverage). If not informed, they are available to the client in AITEX.
11. - The original materials and rests of samples, not subject to test, will be retained in AITEX during the twelve months following the issuance of the report, so that any check or claim which, in his case, wanted to make the applicant, should be exercised within the period indicated. In the case of cosmetic products, it will be ONE MONTH.
12.- This report may only be sent or delivered by hand to the applicant or to a person duly authorised by the same.
13.- The results of the tests and the statement of compliance with the specification in this report refer only to the test sample as it has been analyzed / tested and not the sample / item which has taken the test sample.
14.- The client must attend at all times, to the dates of the realization of the tests.
15.- According to Resolution EA (33) 31, the test reports must include the unique identification of the sample, and any brand or label of the manufacturer may be added. It is not allowed to re-issue test reports of untested sample names (references), they can only be re-issued for error correction or inclusion of omitted data that were already available at the time of the test. The laboratory can not assume responsibility for declaring that the product with the new trade name / trademark is strictly identical to the one originally tested; This responsibility belongs to the client.
16.- This report may not be partially reproduced without the written approval of the issuing laboratory.
17.- The information provided by the client is not covered by the scope of ENAC accreditation.